ONCORUS INC (ONCR) 0.6118 -0.01 (-1.34%)
0.6118 -0.01 (-1.34%)
US68236R1032 - Common Stock - After market: 0.6118 0 (0%)
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
Company now focused on the development of ONCR-021, Oncorus’ lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program...
Oncorus to Participate in Upcoming Investor Conferences
Oncorus to Participate in Upcoming Investor Conferences
ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to...
Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting
ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in glioblastoma...
Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates
Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in the fourth quarter of 2022On track to...
Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates
Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer
New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021...
Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer
New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021
Oncorus to Present at Chardan’s 6th Annual Genetic Medicines Conference
ANDOVER, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to...
Oncorus to Present at the H.C. Wainwright 24th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to...
Oncorus Reports Second Quarter 2022 Financial Results and Provides Business Updates
Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in second half of 2022Company remains on track...
Oncorus Appoints Douglas Fambrough to Board of Directors
-Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 ...
Noteworthy Friday Option Activity: ONCR, CRSR, WBA
Interesting ONCR Call Options For July 15th
Oncorus to Present at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to...
Oncorus to Present at the H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to...
Oncorus Reports First Quarter 2022 Financial Results and Provides Business Updates
Additional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022Preclinical...
Oncorus Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting
– ONCR-021 and ONCR-788 demonstrate robust preclinical anti-tumor efficacy following IV-administration – – vRNA Immunotherapy Platform has the potential...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! It's time to start off another busy day of trading with the biggest pre-market stock movers for Tuesday!
Oncorus Announces Debt Capital Facility with K2 HealthVentures with $20 Million Funded at Closing, Relocation of Corporate Headquarters and Extension of Cash Runway
-Multiple tranche debt financing agreement provides Oncorus with access to up to $45 million- -Use of proceeds intended to support completion of a...